Tumor marker 腫瘤標記

• Raised CEA and no history of cancer

• Elevated CA19-9 and no history of cancer

Suggested readings

1. Tateishi, Ryosuke, et al. "Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review." Hepatology international 2.1 (2008): 17-30.

2. Şeber, Selcuk, et al. "Causes of Elevated Levels of Serum CA 19.9 in Patients without Prior Diagnosis of Malignant Disease." Southern Clinics of Istanbul Eurasia 30.3 (2019).

3. Hu, Ping-Jen, et al. "Clinical evaluation of CA72-4 for screening gastric cancer in a healthy population: a multicenter retrospective study." Cancers 11.5 (2019): 733.

References

AFP

• [2] Tateishi, Ryosuke, et al. "Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review." Hepatology international 2.1 (2008): 17-30.

• [3] Zhang, Jiaxin, et al. "The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis." PloS one 15.2 (2020): e0228857.

• [4] Chang, Te-Sheng, et al. "Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis." Official journal of the American College of Gastroenterology| ACG 110.6 (2015): 836-844.

• [5] Shang, Sufen, et al. "Identification of osteopontin as a novel marker for early hepatocellular carcinoma." Hepatology 55.2 (2012): 483-490.

• [6] Ahn, Dae Geon, et al. "Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea." The Korean journal of internal medicine 31.1 (2015): 46.

• [7] Trevisani, Franco, et al. "Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status." Journal of hepatology 34.4 (2001): 570-575.

• [8] Durazo, Francisco A., et al. "Des‐γ‐carboxyprothrombin, α‐fetoprotein and AFP‐L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma." Journal of gastroenterology and hepatology 23.10 (2008): 1541-1548. 

CA19-9

4. [1] Şeber, Selcuk, et al. "Causes of Elevated Levels of Serum CA 19.9 in Patients without Prior Diagnosis of Malignant Disease." Southern Clinics of Istanbul Eurasia 30.3 (2019).

5. [2] Sato, Yuki, et al. "The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma." BMC cancer 16.1 (2016): 890.

6. [3] Wang, Qing-hai, et al. "Serum CA 19-9 as a good prognostic biomarker in patients with bladder cancer." International Journal of Surgery 15 (2015): 113-116.

7. [4] Alencar, Renata, et al. "CA19-9 as a predictor of worse clinical outcome in medullary thyroid carcinoma." European Thyroid Journal 8.4 (2019): 186-191.

8. [5] TO, Satoshi, and Fumitake GEJYO. "Elevation of serum CA19-9 levels in benign diseases." Internal Medicine 38.11 (1999): 840-841.

9. [6] Kodama, Takahide, et al. "Serum levels of CA19‐9 in patients with non malignant respiratory diseases." Journal of clinical laboratory analysis 21.2 (2007)

10. [7] Long, Niamh M., and Clare S. Smith. "Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging." Insights into imaging 2.6 (2011): 679-698.

11. [8] Doğan, Ümit Bilge, et al. "Relationship of CA 19-9 with choledocholithiasis and cholangitis." Turkish Journal of Gastroenterology 22.2 (2011): 171-177.

12. [9] Maestranzi, S., et al. "The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA." Annals of clinical biochemistry 35.1 (1998): 99-103.

13. [10] Jamaludin, A. Z., et al. "Elevated serum CA 19-9 in association with Hashimoto thyroiditis." Singapore Med J 51.8 (2010): e143-e145.

14. [11] Uygur-Bayramiçli, Oya, et al. "Type 2 dıabetes mellıtus and CA 19-9 levels." World Journal of Gastroenterology: WJG 13.40 (2007): 5357.

15. [12] Koprowski H et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5:957–971.

16. [13] Koprowski H et al. Specific antigen in serum of patients with colon carcinoma. Science. 1981;212:53–55.

17. [14] Tsinrong Lee et al. Carbohydrate antigen 19-9 — tumor marker: Past, present, and future. World J Gastrointest Surg. 2020 Dec 27; 12(12): 468–490.

18. [15] Rawla, Prashanth, Tagore Sunkara, and Vinaya Gaduputi. "Epidemiology of pancreatic cancer: global trends, etiology and risk factors." World journal of oncology 10.1 (2019): 10.

19. [16] Hu, Jian-Xiong, et al. "Pancreatic cancer: A review of epidemiology, trend, and risk factors." World journal of gastroenterology 27.27 (2021): 4298.

20. [17] Sarandakou, Angeliki, Efthimia Protonotariou, and Demetrios Rizos. "Tumor markers in biological fluids associated with pregnancy." Critical reviews in clinical laboratory sciences 44.2 (2007): 151-178.

21. [18] Huang, Junjie, et al. "Worldwide burden of, risk factors for, and trends in pancreatic cancer." Gastroenterology 160.3 (2021): 744-754. 

CA72-4

• [1] Hu, Ping-Jen, et al. "Clinical evaluation of CA72-4 for screening gastric cancer in a healthy population: a multicenter retrospective study." Cancers 11.5 (2019): 733.

• [2] Mariampillai, Anusiyanthan Isaac, et al. "Cancer antigen 72-4 for the monitoring of advanced tumors of the gastrointestinal tract, lung, breast and ovaries." Anticancer Research 37.7 (2017): 3649-3656.

• [3] Feng, Ji-Feng et al. "Prognostic significance of preoperative CA72-4 in patients with esophageal squamous cell carcinoma." Archives of Iranian Medicine 16.6 (2013): 0-0.

• [4] Sabbar, Mortada Basheer, et al. "CA72-4 as a promising prognostic and diagnostic biomarker in Iraqi patients with colorectal cancer." Al-Mustansiriyah Journal of Science 34.1 (2023): 10-15.

• [5] Liu, Peng et al. "Elevated serum CA72-4 levels predict poor prognosis in pancreatic adenocarcinoma after intensity-modulated radiation therapy." Oncotarget 6.11 (2015): 9592.

• [6] Cao, Xi-Shan, et al. "Pleural fluid carbohydrate antigen 72-4 and malignant pleural effusion: a diagnostic test accuracy study." Therapeutic Advances in Respiratory Disease 18 (2024): 17534666231222333.

• [7] Xin, Bing, et al. "NFAT overexpression correlates with CA72-4 and poor prognosis of ovarian clear-cell carcinoma subtype." Reproductive Sciences 28.3 (2021): 745-756.

• [8] HUI, CK, and K. HUI. "Asymptomatic Healthy Population With Raised CA 72-4 Has A Low Prevalence of Malignancy and Does Not Have An Increased Risk of Malignancy on Long-Term Follow-Up." J Comm Med and Pub Health Rep 4.04 (2023).

• [9] Trape Pujol, J., et al. "B-320 Understanding CA 72-4: Exploring False Positives in Clinical Context." Clinical Chemistry 70.Supplement_1 (2024): hvae106-677.